DoW Peer Reviewed Cancer, Clinical Trial Award

General Information Document Type: Grants Notice Funding Opportunity Number: HT942526PRCRPCTA Funding Opportunity Title: DoW Peer Reviewed Cancer, Clinical Trial Award Opportunity Category: Discretionary Opportunity Category Explanation: Funding Instrument Type: Grant Category of Funding Activity: Science and Technology and other Research and Development Category Explanation: Expected Number of Awards: 10 Assistance Listings: 12.420 -- Military Medical Research and Development Cost Sharing or Matching Requirement: No Version: Synopsis 1 Posted Date: May 06, 2026 Last Updated Date: May 06, 2026 Original Closing Date for Applications: Oct 05, 2026 Current Closing Date for Applications: Oct 05, 2026 Archive Date: Nov 04, 2026 Estimated Total Program Funding: $ 45,000,000 Award Ceiling: $ Award Floor: $ Eligibility Eligible Applicants: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility" Additional Information on Eligibility: Additional Information Agency Name: Defense Health Agency Contracting Activity - DHACA Description: Summary: The fiscal year 2026 (FY26) Peer Reviewed Cancer Research Program (PRCRP) Clinical Trial Award (CTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of cancer within at least one of the FY26 PRCRP Topic Areas. Clinical trials proposed may evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first-in-human, phase 0) that evaluate the effects of interventions or inform the design of more advanced trials to large-scale trials (up to phase III) to determine efficacy in relevant patient populations. Distinctive Features Applications to this award mechanism must include a clinical trial. Projects can range from phase 0 to phase III. If an Investigational New Drug (IND) application, Investigational Device Exemption (IDE), or equivalent, is required, a regulatory application must be submitted to the relevant regulatory agency by the Clinical Trial Award application submission deadline. The regulatory application should be specific to the product and indication to be tested in the proposed clinical trial. Applications are required to include patient advocates. Animal studies are NOT allowed under this award mechanism. All preclinical work must be completed prior to the award start date. Link to Additional Information: Grantor Contact Information: If you have difficulty accessing the full announcement electronically, please contact: eBRAP Help Desk Phone: 301-682-5507 Email: help@eBRAP.org eBRAP Help Desk